Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Exact Sciences (EXAS) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an e ...

New industries, while touting disruptions, are some of the biggest incinerators of capital. However, unless you are an experienced investor who has navigated multiple market cycles or have a keen eye for data, you will almost alwaysShri Upadhyaya is a deeply independent investor with over 15 years of hands-on experience across stocks and options. A self-taught investor with real skin in the game, Shri backs most of his Buy and Sell calls with his own capital because writing is clearer when money is on the l ...

Thanks to our global coverage we've ramped up our global macro commentary on our marketplace service here on Seeking Alpha, The Value Lab . We focus on long-only value ideas, where we try to find international mispriced equities and target a portfolio yield of about 4% . We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, us at the Value Lab might be of inspiration.The iSh ...

Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount, e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions, and wide moat compounders). Sign up here to get s ...

Since my last write-up on Gambling.com ( GAMB ), the stock has had a disappointing performance, dropping by more than 20%. This came as a shock to me since the company shows impressive revenueI'm a self taught equity analyst, I run a consultation firm in South Africa where we help clients with estimating the value of construction projects, over the past 5 years I've been retail investing and learning more about how the stock market works, following the work of Ben Graham and Joel Greenblatt while also learn ...

投资策略与服务 - 专注于长期价值投资 寻找国际市场中定价错误的股票 目标投资组合收益率约为4% [1] - 过去5年表现优异 通过深入参与国际市场获得成功 [1] - 提供实时投资组合更新 24/7问答服务 定期全球市场新闻报告 会员股票建议反馈 每月新交易建议 季度财报分析 每日宏观观点 [2] 投资产品 - F/m美国国债10年期ETF(UTEN)久期约为8年 主要投资于10年期国债 对利率变化敏感 [2] 投资团队 - Valkyrie Trading Society团队专注于高确信度且冷门的发达市场投资机会 这些机会下行风险有限 在当前经济环境下可能产生非相关性和超额回报 [3] - 该团队采用纯多头投资策略 [3]

吉利银河系列产品潜力 - 吉利银河系列作为新产品故事(NPS)在纯电动车(BEV)和插电混动车(PHEV)同价位区间具备显著上行空间 其产品功能具有较强吸引力 [1] - 当前市场情绪较前期有所改善 此前市场对吉利新能源车(NEV)发展进度感到失望 [1] 分析师背景 - 分析师专注于中美两国消费 discretionary 和金融服务领域 投资周期为0.5-2年 [1] - 分析师持有多仓倾向且侧重中国市场 目前寻求全球化分散投资 [1]

分析师背景 - 分析师拥有10年个人投资经验及5年股票分析经验 专注于价值型公司研究 [1] - 研究重点为具备持续自由现金流 低杠杆率 可持续债务且具有高复苏潜力的商品生产类公司 [1] - 偏好分析石油天然气 金属矿业等非热门行业及美国以外司法管辖区的企业 聚焦新兴市场高利润率标的 [1] - 方法论强调股东回报导向 关注长期稳定的股票回购或股息分配政策 [1] - 学术背景为金融硕士(公司估值方向)及经济学学位 研究动机是为投资者社区提供独立分析 [1] 研究立场 - 所有分析均为个人观点 不构成买卖建议 [1] - 当前未持有相关公司头寸 未来72小时无交易计划 [1] - 与其他作者无商业关联 研究覆盖领域及观点相互独立 [1] 注：文档2内容为平台免责声明 与公司/行业分析无关 已按指令跳过

公司业绩与股价表现 - 洛克希德·马丁公司股价在2025年第二季度财报发布后单日暴跌10.8%，主要因一次性项目亏损16亿美元及其他费用1.69亿美元拖累，导致每股收益(EPS)仅1.46美元[1][3] - 这是公司过去三个季度中第二次因类似问题导致业绩大幅低于预期，此前2025年1月也曾因17.2亿美元资产减记引发股价单日下跌9.2%[3][4] - 尽管业绩波动，公司维持2025全年营收指引737.5-747.5亿美元和自由现金流(FCF)66-68亿美元的预测[12][16] 业务结构与行业对比 - 公司业务集中于美国政府及盟国国防订单，涉及战斗机、导弹、太空系统等长期合同，但部分项目利润率较低且增长停滞，过去五年营收仅增长12%[6][10] - 行业竞争对手表现强劲：RTX保持稳定内生增长，诺斯罗普·格鲁曼创股价新高并上调全年指引，波音近期赢得价值数百亿美元的战斗机合同[9][10] - 公司当前股息收益率3.2%为国防承包商中最高，且是唯一股息率超过2%的主要国防企业[13][19] 战略调整与估值分析 - 公司启动项目审查流程以优化遗留项目执行，短期虽导致亏损但旨在提升长期运营效率[5][15] - 当前市值962亿美元对应市销率1.3倍(10年中位数1.7倍)，市现率14.4倍(10年中位数19.2倍)，估值处于历史低位[16][17] - 自由现金流指引显示公司仍具备资本回报能力，2025年计划维持股票回购和股息支付[12][20]